Kean Woodmansey

Pharma perspectives: The role of digital and software solutions in pharmaceutical R&D

Mar 31, 2025 | Blogs, Pharma | 0 comments

It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.

Integration

Advanced analytical systems, like mass spectrometers and liquid chromatography systems, have a crucial role to play in guiding the pharmaceutical industry’s journey toward digital integration. We prioritize the development of expansive digital platforms that seamlessly merge various systems and data sources and establish robust standards. Embracing innovative technologies such as the internet of things and advanced analytics will allow us to implement real-time monitoring and predictive maintenance, ultimately optimizing operational efficiency for pharmaceutical companies.

Here is an example of An automated, real-time measurement of the kinetic hydrolysis of a glucuronide using the Echo® MS+ system with ZenoTOF 7600 system

Software

Embedding compliance features into our solutions is crucial to ensure alignment with evolving regulatory frameworks. Equally important, is a commitment to providing comprehensive training and continuous support to facilitate the smooth adoption of digital solutions within pharmaceutical companies. This proactive approach will empower our customers to navigate the complexities of digital transformation confidently and competently.

To allow our existing and potential new customers to trail our new software features, we provide a virtual trial of SCIEX OS software.

Ultimately, we should aim to drive the industry toward achieving operational excellence within the interconnected digital landscape. Through ongoing innovation and strategic partnership, life science technology providers can make a meaningful impact in shaping the future of pharmaceutical operations, ensuring agility, resilience, and efficacy in an increasingly digital world.

Learn more about how SCIEX can help here

ADC analytics FAQs: Answering the most common questions about ADC characterization

Antibody-drug conjugates (ADCs) have emerged as one of the fastest-growing classes of biotherapeutics, combining the targeting specificity of monoclonal antibodies with the potency of cytotoxic payloads. However, this unique architecture also introduces significant analytical complexity. From drug-to-antibody ratio (DAR) distributions and charge variants to conjugation sites and structural modifications, ADCs present multiple, interconnected sources of heterogeneity that must be understood to ensure product quality and performance.

Sterile but toxic: Cereulide detection in food matrices

In a recent webinar, Ming Gao, Ph.D., Senior Research Chemist at Mérieux NutriSciences, explored the growing challenge of cereulide contamination in food products and the analytical strategies needed to detect this heat-stable toxin at trace levels. The session examined how LC-MS/MS can help laboratories overcome the limitations of traditional microbiological screening and meet emerging regulatory requirements.

How SCIEX Now empowers mass spec users to work with more control, clarity and confidence

In this interview, Andy Wilcox, Senior Market Development Manager, Aftermarket and Software, speaks with Susanna Baqué, Senior Director of Global Customer Experience, about how SCIEX Now gives customers one connected digital workspace to manage instruments, reduce time spent searching for information, resolve issues faster and keep their laboratory running more efficiently and with greater confidence.

Posted by

Kean Woodmansey

Senior Product Manager, Echo® MS+ system Kean Woodmansey is the Senior Product Manager for the Echo® MS system at SCIEX. In this role, he is responsible for the strategic success of the Echo MS+ portfolio. Kean spent the first part of his career working in contract research organizations, doing bioanalysis, before moving into pharma market development and product management.

0 Comments